Detalhe da pesquisa
1.
Binding kinetics, potency, and selectivity of the hepatitis C virus NS3 protease inhibitors GS-9256 and vedroprevir.
Biochim Biophys Acta
; 1840(12): 3292-8, 2014 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-25139683
2.
Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451.
Antimicrob Agents Chemother
; 58(2): 647-53, 2014.
Artigo
Inglês
| MEDLINE | ID: mdl-23939899
3.
No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B.
Clin Gastroenterol Hepatol
; 12(12): 2106-12.e1, 2014 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-24929235
4.
Novel, sulfonamide linked inhibitors of the hepatitis C virus NS3 protease.
Bioorg Med Chem Lett
; 24(3): 969-72, 2014 Feb 01.
Artigo
Inglês
| MEDLINE | ID: mdl-24405705
5.
Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B.
Hepatology
; 56(6): 2018-26, 2012 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-22544804
6.
Localization of a class III myosin to filopodia tips in transfected HeLa cells requires an actin-binding site in its tail domain.
Mol Biol Cell
; 14(10): 4173-80, 2003 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-14517327
7.
In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons.
Antiviral Res
; 100(2): 439-45, 2013 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-24013001
8.
Cellular growth kinetics distinguish a cyclophilin inhibitor from an HSP90 inhibitor as a selective inhibitor of hepatitis C virus.
PLoS One
; 7(2): e30286, 2012.
Artigo
Inglês
| MEDLINE | ID: mdl-22347373
9.
The kinase domain alters the kinetic properties of the myosin IIIA motor.
Biochemistry
; 47(8): 2485-96, 2008 Feb 26.
Artigo
Inglês
| MEDLINE | ID: mdl-18229949